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Background: Approximately 30 % of breast cancer patients receive chemotherapy, yet little is known about
influences of current regimens on circulating lymphocyte levels and phenotypes. Similarly, clinico-pathological
factors that modify these influences, and implications for future immune health remain mainly unexplored.
Methods: We used flow-cytometry to assess circulating lymphocyte levels and phenotypes in 88 primary breast
cancer patients before chemotherapy and at time-points from 2 weeks to 9 months after chemotherapy
completion. We examined circulating titres of antibodies against pneumococcal and tetanus antigens using ELISAs.
Results: Levels of B, T and NK cells were significantly reduced 2 weeks after chemotherapy (p < 0.001). B cells
demonstrated particularly dramatic depletion, falling to 5.4 % of pre-chemotherapy levels. Levels of all cells
recovered to some extent, although B and CD4+ T cells remained significantly depleted even 9 months post-
chemotherapy (p < 0.001). Phenotypes of repopulating B and CD4+ T cells were significantly different from, and
showed no sign of returning to pre-chemotherapy profiles. Repopulating B cells were highly depleted in memory
cells, with proportions of memory cells falling from 38 % to 10 % (p < 0.001). Conversely, repopulating CD4+ T cells
were enriched in memory cells, which increased from 63 % to 75 % (p < 0.001). Differences in chemotherapy
regimen and patient smoking were associated with significant differences in depletion extent or repopulation
dynamics. Titres of anti-pneumococcal and anti-tetanus antibodies were both significantly reduced post-
chemotherapy and did not recover during the study (p < 0.001).
Conclusion: Breast cancer chemotherapy is associated with long-term changes in immune parameters that should
be considered during clinical management.
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Breast cancer is the most common malignancy in
women and causes more than half a million deaths an-
nually worldwide [1]. Typical treatment is surgical
tumour resection, usually combined with endocrine
therapy, biologics, radiotherapy, and/or cytotoxic
chemotherapy. Chemotherapy is a component of therapy
in ~30 % of cases [2], and is recommended when tu-
mours display poor prognosis features, including nodal
involvement, large size, high grade, and/or lack of* Correspondence: t.hughes@leeds.ac.uk; clivecarter@nhs.net
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Current chemotherapy regimens for primary disease in-
clude anthracycline-based protocols and sequential use
of anthracyclines and taxanes, and these give substantial
reductions in metastatic recurrence rates and increases
in overall survival [4, 5]. However, chemotherapy is also
associated with wide ranging adverse effects on non-
target tissues, including substantial impacts on the im-
mune system. Neutropenia is often regarded as the most
serious haematological toxicity and can be associated
with infections that may force chemotherapy dose re-
duction and/or delays that may compromise treatment
[6, 7]. Neutrophil levels are known to recover afteris distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 1 Clinico-pathological features of the breast cancer
patients included in the study
number (%)(n = 88)
Age range: 24-74
mean: 52
Smoking smokers 25 (28)
non-smokers 63 (72)
Tumour grade 1 2 (2)
2 37 (42)
3 49 (56)
Tumour size <2cm 42 (48)
2 - 5cm 33 (37)
> = 5cm 13 (15)
Surgery breast conservation 53 (60)
mastectomy 34 (39)
no surgery 1 (1)
ER/PR status positive 57 (65)
negative 31 (35)
Her2 status positive 16 (18)
negative 72 (82)
Nodal status negative 38 (43)
positive 50 (57)
Chemotherapy EC/FEC 39 (44)




Endocrine none 31 (35)
tamoxifen 37 (42)
aromatase inhibitors 20 (23)
Radiotherapy yes 73 (83)
no 15 (17)
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neutropenia is not thought to have common persistent
consequences. Chemotherapy also affects the adaptive
immune system, and by contrast, there is evidence these
effects may cause more long-lived changes to immunity,
although studies in the context of modern chemotherapy
regimens and particularly with respect to B lymphocytes
are lacking.
Many studies have reported effects of chemotherapy
on lymphocytes in breast cancer patients during the
therapy itself or up to 3 months after the last chemo-
therapy cycle, with a consensus that chemotherapy
reduces circulating lymphocyte levels [8–12]. Lympho-
penia shortly following chemotherapy for many other
cancers is also well established [13, 14]. Much less is
known about whether, when and how lymphocyte popu-
lations recover in the longer-term, and what is known is
often conflicting. For example, significantly depressed T
and B cell numbers as long as 12 months following com-
pletion of chemotherapy have been reported [15], while
others have found all lymphocyte populations except
CD4+ T cells to recover to pre-treatment levels at the
same time-point, even after a particularly dose intense
chemotherapy regimen [16]. A key issue is that extrapo-
lating currently relevant conclusions from this aging lit-
erature may be impossible as modern chemotherapy
regimens differ substantially from those in much of the
literature. Nevertheless, common themes that have some
support in more modern literature are discernable. With
respect to T cells, it appears that CD8+ T cell levels re-
cover more quickly after chemotherapy than CD4+ T
cells [9–11, 13, 16] and that repopulating cells comprise
a reduced proportion of naïve cells, and an increased
memory component [16, 17]. With respect to B cells,
there is a paucity of published data beyond the generic
observation that B cell levels are reduced post-
chemotherapy. The phenotype of repopulating B cells re-
mains essentially unknown, and there is no published
understanding of how B cell repopulation might impact
on subsequent immunity. In this work we have analysed
lymphocyte levels and phenotypes in a cohort of breast
cancer patients before, and at various time-points after
chemotherapy in an effort to understand the longer-
term changes associated with chemotherapy and the
clinico-pathological factors that may influence them, the
interplay between the various repopulating lymphocyte
subtypes, and the potential implications of repopulation
for future immune health.
Methods
Ethical issues, participants, sample collection
Ethical approval was obtained from Leeds (East) Re-
search Ethics Committee (ref 06/Q1206/217). Patients at
Leeds Teaching Hospitals NHS Trust diagnosed betweenJune 2011 and Jan 2012 with operable primary breast
cancer and receiving chemotherapy were eligible for the
study. Exclusion criteria were: male; aged >75 years;
long-term steroid/immunosuppressive drug use; previ-
ous breast cancer history; previous chemotherapy in last
10 years. 88 patients were recruited and peripheral blood
– two separate 4ml samples taken in an ethylene-
diamine-tetra acetic acid vacuette tube (Greiner Bio-
one) (for lymphocyte analyses) and a clot activator/gel
tube (Greiner Bioone) (for serum separation) – was
taken prior to starting chemotherapy and at 2 weeks, 3,
6 and 9 months after the last chemotherapy cycle. In 26
patients, pre-chemotherapy samples were unavailable,
and these patients are excluded from analyses relative to
pre-chemotherapy levels, and data for pre-chemotherapy
time-points are n = 62. Extensive clinico-pathological
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defined ‘smokers’ as all current smokers (irrespective of
number of cigarettes smoked and duration of smoking);
‘non-smokers’ were all ex-smokers and non-smokers.
Healthy controls were also recruited (n = 17) and periph-
eral blood taken as above on a single occasion. All par-
ticipants gave informed written consent.
Lymphocyte subset analyses
Absolute numbers and percentages of lymphocyte sub-
sets were determined by flow cytometry using Trucount
tubes (Becton Dickinson) and a ‘lyse non-wash’ protocol,
according to manufacturer’s instructions. All samples
were tested <16h after collection. Briefly, 50μl whole
blood was incubated with 15μl multitest reagents (CD3/
CD8/CD45/CD4 and CD3/CD16-CD56/CD3/CD45; Bec-
ton Dickinson) (15min, dark, room temperature). Lysing
buffer (450μl) was added and samples were incubated for
a further 15min prior to data acquisition using multiset
software on a FACSCalibur flow cytometer (Becton Dick-
inson). Using this method, the following lymphocyte sub-
sets were measured: T (CD45+ CD3+); B (CD45+ CD19+);
helper T (CD45+ CD3+ CD4+); cytotoxic T (CD45+ CD3+
CD8+); NK (CD45+ CD3− CD56+ and/or CD16+). For
more detailed phenotyping 100μl blood was incubated
with mixtures of antibodies at appropriate concentrations
(outlined below) (20min, room temperature, dark). Sam-
ples were subsequently treated with 3ml lysis solution and
were washed twice in 1 % FBS in PBS. Cells were resus-
peded in 400μl 5 % formaldehyde in PBS and 25,000
events were acquired on a FACSCanto flow cytometer be-
fore analysis in CellQuest (Becton Dickinson). Positive ex-
pression was defined using negative control antibody
staining to define the negative/positive cut offs, and these
were consistently applied in all samples. Hi/low cut offs
were arbitrary, but consistently applied in all samples.
Antibodies used were CD19-PerCP (clone SJ25C1);
CD27-FITC/Pe (M-T271); IgD-FITC (IA6-2); CD24-Pe
(ML5); CD38-APC (HB7), CD3PerCP (SK7); CD4-APC
(SK3); CD56RA-Pe (HI100), CD45RO-FITC (UCHL-1),
CD62L-FITC (Dreg56) CD31-Pe (L133.1). Using this
method the following lymphocyte subtypes were quanti-
fied: naïve B (CD19+ CD27− IgD+); non-switched memory
B (CD19+ CD27+ IgD+); switched memory B (CD19+
CD27+ IgD−); transitional B (CD19+ CD24hi CD38hi);
naïve T (CD4+ RA+ RO− or CD4+ RA+ CD62L+); memory
T (CD4+ RA− RO+); and recent thymic emigrants (CD4+
CD45RA+ CD31+).
Serum separation and determination of antibody titres
Serum was separated from clot activator/gel blood sam-
ple tubes after centrifugation (~500g, 20min, room
temperature), and was stored at -20 °C. Tetanus and
pneumococcal antibody titres and thresholds for“suboptimal” and “inadequate” levels were determined
by enzyme immunoassay kits (The Binding Site) follow-
ing the manufacturer’s protocols.
Statistical analysis
Analyses were performed using SPSSv17 (IBM). Tests
used included Mann-Whitney U, Wilcoxan signed rank,
Kruskal Wallis, related samples Friedman’s 2 way
ANOVA, Pearson Chi square test, Linear-by-linear Asso-
ciation and Spearman’s correlation. Values for p < 0.05
were considered statistically significant.
Results
Lymphocyte subtypes show differential depletion and
recovery after chemotherapy
In order to understand better the effects of chemother-
apy on the adaptive immune system, we conducted a
longitudinal investigation of lymphocyte levels and phe-
notypes before and at time-points from 2 weeks to 9
months after the end of chemotherapy. 88 patients
treated with chemotherapy for primary breast cancer
were included and extensive clinico-pathological data
concerning the patients were collected (Table 1). Levels
of peripheral blood B cells, CD4+ T cells, CD8+ T cells,
and NK cells were determined and are presented as ab-
solute levels (Fig. 1a), and as levels relative to the
matched pre-chemotherapy level for each patient
(Fig. 1b).
Levels of each lymphocyte subtype prior to chemo-
therapy were within the normal range in all cases, with a
relatively large degree of variation across the cohort as
expected within any population; these levels in patients
did not significantly differ from those in healthy subjects
of a similar age range (Additional file 1: Table S1). 2
weeks after the end of chemotherapy, significant deple-
tions of all 4 lymphocyte subtypes were noted as com-
pared to pre-chemotherapy levels (p < 0.001). B cells
demonstrated a particularly dramatic depletion, falling
to a median of 5.4 % of pre-chemotherapy levels. In the
majority of patients (55.7 %), B cells were reduced to <2
% of their original levels, while 8 individuals showed ab-
solute B cell counts as low as <1 cell/μl. Levels of each
lymphocyte subtype demonstrated gradual recovery dur-
ing the study, until by 9 months post-chemotherapy
levels of CD8+ T and NK cells were close to, and no lon-
ger significantly different from pre-chemotherapy levels.
However, there was only partial recovery of B and CD4+
T cells after 9 months (reaching medians of only 69 %
and 60 % of initial levels respectively) and these levels
remained significantly different from pre-chemotherapy
levels at this time-point (p < 0.001). In addition, in both
of these cell types there was no evidence of continued
recovery from 6 months (68 % and 60 % of initial levels)
to 9 months.
Fig 1 Lymphocyte subtypes show differential depletion and recovery after chemotherapy. Absolute numbers of the lymphocyte subgroups
shown were determined by multi-parameter flow cytometry on peripheral blood samples taken from 88 breast cancer patients either before
chemotherapy (pre) or at various time-points after the end of chemotherapy (2 weeks [2w]; 3, 6 or 9 months [3m, 6m, 9m]). Data are shown as
absolute counts (a) or relative to the matched pre-chemotherapy level (b). Boxes represent 50 % of the data, with medians (lines), interquartile
ranges (whiskers) and individual outliers (circles). * p < 0.001 (shown for selected comparisons only); ns ‘not significant’
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levels for each subtype were highly correlated (Spearman’s
coefficients 0.56-0.84; p < 0.001), with particularly strong re-
lationships within the B and T cells (coefficients all >0.74),
demonstrating that the greatest or least depletion of each
subtype typically occurred in the same individuals. Recon-
stitution relative to initial levels for the different subtypes
was, by contrast, only weakly correlated between B, CD4+
T and NK cells, with coefficients of 0.267-0.383 (p < 0.05) at
3 and 6 months post-chemotherapy and no significant rela-
tionships at 9 months, suggesting that recovery of these cell
types was broadly independent. Exceptions to this were be-
tween CD8+ and CD4+ T cells, where moderately strong re-
lationships were maintained at every recovery time-point
(coefficients 0.48-0.72; p < 0.001), and between CD8+ T and
NK cells, which behaved similarly (coefficients 0.47-0.52;
p < 0.001), indicating that recoveries of these pairs of cell
populations may be functionally related.
Subsequently, we focused on the B and CD4+ T sub-
types, as these remained significantly depressed through-
out the study. We investigated whether their degrees of
depletion or kinetics of reconstitution were related to
pre-chemotherapy levels, by comparing depletion and
reconstitution in patients within the top or bottomtertiles of pre-chemotherapy levels (Fig. 2). For B cells,
patients with high and low initial levels suffered similar
degrees of depletion (to 5.7 % and 6 %; p = 0.93) and
levels recovered at similar rates (for example, to 63 %
and 64 % at 9 months; p = 0.71); there was no evidence
that pre-chemotherapy levels impacted on relative deple-
tion and reconstitution at any time-point. For CD4+ T
cells, patients with high and low initial levels similarly
showed no difference in depletion (to 42 % and 44 %;
p = 0.62). However, reconstitution of these cells differed
significantly between the groups (p < 0.02). Patients with
the lowest initial levels recovered CD4+ T cells to 73 %
of these levels after 6 months, although no further re-
covery was seen at 9 months (72 %). This contrasts with
patients with the highest initial levels, where levels
reached only 48 % and 53 % of these levels at 6 and 9
months respectively. This reduced relative recovery was
not solely a consequence of presenting data as a propor-
tion of the higher initial levels in this group, as slower
recovery was also evident in a comparison of increases
in absolute counts. Patients in the upper tertile of initial
levels showed smaller numerical increases in absolute
counts of CD4+ T cells than those seen in patients in the
lower tertile at all three recovery time-points.
Fig 2 B cell recovery is not influenced by pre-chemotherapy levels of B cells while CD4+ T cell recovery is significantly impaired in patients with
the highest pre-chemotherapy CD4+ T cell levels. Patients were divided into three tertiles based on pre-chemotherapy absolute counts of B cells
(top left) or CD4+ T cells (bottom left). Relative levels of these cell types at time-points after the end of chemotherapy (2 weeks [2w]; 3, 6 or 9
months [3m, 6m, 9m]) are shown for the upper and lower tertiles (right panels) and were compared pairwise at each time-point (* p < 0.02).
Boxes represent 50 % of the data, with medians (lines), interquartile ranges (whiskers) and individual outliers (circles)
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decreases proportions of memory B cells
We next investigated the effect of chemotherapy on B
phenotypes in more detail. CD19+ B cells were analysed
as: naïve (CD27− IgD+); non-switched memory (CD27+
IgD+); switched memory (CD27+ IgD−), transitionalFig 3 After chemotherapy B cells comprise more naïve cells and fewer me
even 9 months after chemotherapy. B cell subtypes were quantified by mu
proportion of the total B cell pool. Data are shown for samples taken pre-c
of chemotherapy. Boxes represent 50 % of the data, with medians (lines), in(CD24hi CD38hi), and as a group with potential regula-
tory activity (CD24hi CD27+). Data are expressed as pro-
portions of total B cells at each time point (Fig. 3),
although note that levels of total B cells were too low 2
weeks after chemotherapy to allow analysis of these sub-
compartments.mory cells, a change that does not show a trend towards normalising
lti-parameter flow cytometry and their numbers are presented as the
hemotherapy (pre) and 3, 6, and 9 months (3m, 6m, 9m) after the end
terquartile ranges (whiskers) and individual outliers (circles). * p < 0.001
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(14 % non-switched; 23 % switched) of peripheral B cells
while at 3 months post-chemotherapy the B cell compart-
ment was radically different, with only 14 % memory cells
(5 % non-switched; 9 % switched; both p < 0.001). Interest-
ingly, at later time-points the proportions of memory cells
decreased even further and showed no sign of returning to
pre-chemotherapy levels. Correspondingly, the proportions
of naïve B cells increased from 54 % pre-chemotherapy to
80 % 3 months after chemotherapy (p < 0.001), and contin-
ued to increase reaching 85 % after 9 months. This change
in B cell composition is strikingly represented as the ratio
of naïve cell numbers to memory cell numbers, which was
1.31 pre-chemotherapy and increased dramatically to 8.55
at 9 months after chemotherapy (p < 0.001). Transitional B
cells (CD24hi CD38hi) represented 5 % of total B cells pre-
chemotherapy and this proportion greatly expanded at 3
months post-chemotherapy to 23 % (p < 0.001), before then
progressively falling, reaching 14 % by 9 months and
thereby showing a trend at later time-points to return to
pre-chemotherapy levels. Finally, CD24hi CD27+ B cells,
which have been reported to have a regulatory function
[18], were found to be reduced as a percentage of total B
cells at all time-points post-chemotherapy compared to the
levels observed prior to treatment (p = 0.001), further
emphasising the reduced expression of CD27 on B cells
post-chemotherapy.
Chemotherapy decreases proportions of naïve and
increases proportions of memory CD4+ T cells
CD4+ T cell phenotypes were also analysed further to
differentiate naïve from memory cells (Fig. 4). NaïveFig 4 After chemotherapy CD4+ T cells comprise fewer naïve cells and mo
normalising even 9 months after chemotherapy. CD4+ T cell subtypes wer
presented as the proportion of the total CD4+ T cell pool. Data are shown
(3m, 6m, 9m) after the end of chemotherapy. Boxes represent 50 % of the
outliers (circles). * p < 0.001cells, defined as CD45RA+ RO−, made up 37 % of the
entire CD4+ T cell pool pre-chemotherapy. This propor-
tion was significantly reduced to 32 % 2 weeks post-
chemotherapy (p < 0.001) and continued to fall over the
course of follow up to only 25 % at 9 months post-
chemotherapy. Similar significant findings were
uncovered using the alternative markers CD45RA+
CD62L+ to identify naïve cells (47 % initially, falling to
35 % 2 weeks post-chemotherapy, and then 32 %, 31 %
and 33 % at the same follow up time-points; p < 0.01 for
initial levels compared to every subsequent time-point).
Conversely, the proportion of memory cells, defined as
CD45RA− RO+, increased from 63 % pre-chemotherapy
to 68 % 2 weeks post-chemotherapy (p < 0.001) and then
increased progressively during follow up to 75 % at 9
months post-chemotherapy. When expressed as a ratio
of naïve to memory cells within the CD4+ T cell
compartment, the value dropped from 0.6 pre-
chemotherapy to 0.47 at 2 weeks post-chemotherapy
(p < 0.001) and continued to fall to 0.35, 0.34 and 0.33 at
3, 6 and 9 months respectively (p < 0.001), indicating
that chemotherapy preferentially impacted on naïve
cells and that this population failed to recover. Further
evidence for a preferential and long-term influence on
immature cells was provided from analysis of levels of
positive expression of CD31 on CD45RA+ CD4+ T cells;
this has been proposed as a marker of recent thymic
emigrants [19, 20]. These cells decreased from 22 % of
the CD4+ T cell pool pre-chemotherapy to 18 % at 2
weeks post-chemotherapy (p < 0.001), and continued to
fall to 12 % after 9 months (p < 0.001) (Additional file 2:
Figure S1).re memory cells, a change that does not show a trend towards
e quantified by multi-parameter flow cytometry and their numbers are
for samples taken pre-chemotherapy (pre) and 3, 6, and 9 months
data, with medians (lines), interquartile ranges (whiskers) and individual
Fig 5 Differences in chemotherapy regimen correlate with the
extent of B cell and CD4+ T cell depletion and with the dynamics of
B cell recovery. Patients received anthracycline-based chemotherapy
(EC/FEC, open boxes; n = 39) or anthracyclines followed by taxanes
(EC + TAX, filled boxes; n = 44). Peripheral B cell and CD4+ T cells
were quantified by multi-parameter flow cytometry either before
chemotherapy (pre) or at time-points after the end of chemotherapy
(2 weeks [2w]; 3, 6 or 9 months [3m, 6m, 9m]). Data are shown as
absolute counts (left panels) or relative to the matched pre-
chemotherapy level (right panels). Boxes represent 50 % of the data,
with medians (lines), interquartile ranges (whiskers) and individual
outliers (circles). *p < =0.05 **p < 0.01
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switched memory B cells
CD4+ T cells have a key role in B cell activation and
maturation by stimulating class switching. Therefore, we
next examined whether levels of CD4+ T cells were asso-
ciated with different compositions of the B cell pool be-
fore chemotherapy or during recovery. No correlations
were evident pre-chemotherapy. However, correlations
were evident during reconstitution of the lymphocyte
pool from 3 months to 9 months post-chemotherapy.
Absolute numbers of CD4+ T cells correlated signifi-
cantly with absolute numbers of switched memory B
cells at all three time points (3, 6 and 9 months:
coefficient 0.22 [p < 0.05], 0.34 [p = 0.002] and 0.32
[p = 0.005]) and this was reflected in a negative correl-
ation with the naïve to memory ratio within the B cell
pool (3, 6 and 9 months: coefficient -0.21 [p < 0.05],
-0.29 [p = 0.01] and -0.24 [p = 0.035]).
Differences in chemotherapy regimen influence depletion
and repopulation dynamics
Next, we examined whether any clinico-pathological
factors were significantly associated with differences
in chemotherapy response of B or CD4+ T lympho-
cytes. Factors tested included patient age, smoking
status, tumour size, tumour grade, lymph node status,
hormone receptor status, radiotherapy treatment and
chemotherapy regimen. Correlations identified are de-
scribed below.
We found that variations in chemotherapy regimens
had significant influences on both B and CD4+ T cells
(Fig. 5). Patients within our cohort were treated with
anthracycline-based regimens (epirubicin and cyclophos-
phamide [EC], or 5-flurouracil, epirubicin and cyclo-
phosphamide [FEC]) for 6 cycles, or alternatively were
treated with 2 EC cycles followed by further cycles of
the taxane, docetaxel [EC + TAX]. It should be noted
that patients who received docetaxel also received Gran-
ulocyte Colony Stimulating Factor (G-CSF) in order to
combat neutropenia [7]. The patients in the EC/FEC and
the EC + TAX groups did not significantly differ in their
pre-chemotherapy levels of either B or CD4+ T cells
(Fig. 5, left panels). However, patients receiving EC/FEC
showed significantly greater B cell depletion compared
to the EC + TAX group at 2 weeks after treatment (de-
pleted to 3 % vs 8 % respectively; p < 0.001). Surprisingly,
the EC/FEC group, who suffered the greatest depletion,
recovered B cells significantly more quickly than the EC
+ TAX group, with the difference between the groups re-
versed and significant at both 6 months (p = 0.04) and 9
months (p = 0.03). At this 9 months time-point, the
levels in the EC/FEC group were no longer significantly
different from before chemotherapy (p = 0.248) and can
be regarded as having recovered completely, while levelsin the EC + TAX group remained significantly depressed
(64 % of pre-chemotherapy levels; p < 0.001). Similarly to
B cells, CD4+ T cells were also depleted more severely in
the EC/FEC group (37 % vs 59 %; p = 0.002), however, by
contrast with B cells, CD4+ T cell recovery did not differ
between the groups.Patients who smoke reconstitute B cells more slowly and
have more CD4+ T cells pre-chemotherapy
A further factor that influenced lymphocyte levels was
smoking. Smokers and non-smokers had similar levels of
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stantially and significantly impaired in the smokers (Fig. 6,
top panels), reaching only 51 % of pre-chemotherapy
levels after 9 months as compared to 80 % in the non-
smokers (p = 0.005). With respect to CD4+ T cells,
smokers had significantly raised levels before chemother-
apy (p = 0.008), but smoking did not appear to impact on
the dynamics of CD4+ T cell repopulation (Fig. 6).Fig 6 Smoking impacts on lymphocyte subtypes and their response to
by multi-parameter flow cytometry either before chemotherapy (pre) o
or 9 months [3m, 6m, 9m]). Patients were divided into non-smokers (o
as absolute counts (left panels) or relative to the matched pre-chemot
medians (lines), interquartile ranges (whiskers) and individual outliers (cChemotherapy reduces serum pneumococcal and tetanus
antibody titres
Given the profound changes in levels and phenotypes of
B and CD4+ T cells, we next investigated whether circu-
lating antibody levels were also altered and thereby that
antibody-mediated immunity might potentially be af-
fected. We examined titres of antibodies against
pneumococcal and tetanus antigens, since immuno-chemotherapy. Peripheral B cell and CD4+ T cells were quantified
r at time-points after the end of chemotherapy (2 weeks [2w]; 3, 6
pen boxes; n = 63) or smokers (filled boxes; n = 25). Data are shown
herapy level (right panels). Boxes represent 50 % of the data, with
ircles). *p < =0.05 **p < 0.01
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populations because of national vaccination programmes.
Firstly, we noted that titres pre-chemotherapy within
our patient cohort were relatively low overall, with some
patients showing titres that would be clinically regarded
as offering insufficient protection against the infectious
agents (15 % of patients were defined as “suboptimal”
and 2 % “inadequate” for anti-pneumococcus; 21 % “sub-
optimal” for anti-tetanus; Fig. 7 top panels). This may
reflect reduced protection associated with older age [21]
and/or an extended time period after vaccination, or it
may be that some patients had not had been vaccinated
at all. Nevertheless, chemotherapy was associated with
significant changes in titres (Fig. 7), even on the back-
ground of low initial levels. At 2 weeks post-chemotherapy,
pneumococcal antibody levels were lower than the pre-
chemotherapy level in all patients tested (p < 0.001), and
they remained significantly lower than pre-chemotherapy
levels overall at 3 and 9 months (p < 0.001). At 9 months
numbers of patients with levels defined as suboptimal
(19 %) or inadequate (6 %) were both increased as com-
pared to pre-chemotherapy. Levels of tetanus antibodiesFig 7 Antibodies against specific antigens are depleted and recover inco
peripheral blood samples taken from breast cancer patients either befor
chemotherapy (2 weeks [2w]; 3 or 9 months [3m, 6m, 9m]). Data are sho
pre-chemotherapy level (bottom panels). Boxes represent 50 % of the d
ual outliers (circles). * p < 0.001were also significantly reduced 2 weeks post-chemotherapy
(p = 0.001) and remained so for the whole study period
(p < 0.05), although the reduction was less striking than for
anti-pneumococcus. In this case the proportions of patients
with suboptimal or inadequate levels of antibody did not
differ between 9 months and pre-chemotherapy.
Levels of both antibodies did not correlate with levels of
total B cells, the levels of the B cell subtypes described previ-
ously or with chemotherapy regimen. Antibody levels did,
however, show some correlations with smoking. Anti-
pneumococcal antibody levels were significantly higher be-
fore chemotherapy in non-smokers as compared to smokers
(p < 0.05) although this difference did not maintain signifi-
cance after chemotherapy. By contrast, anti-tetanus antibody
levels were not significantly different in these groups pre-
chemotherapy, but recovery of levels was significantly im-
paired in smokers when assessed as a proportion of initial
levels, with smokers reaching only 72 % of initial levels as
compared to 94 % in non-smokers (p < 0.02). In the smokers,
these levels were still significantly depressed (p= 0.03), while
in the non-smokers they were no longer significantly differ-
ent from pre-chemotherapy levels.mpletely after chemotherapy. Antibody titres were determined in
e chemotherapy (pre) or at various time-points after the end of
wn as serum concentrations (top panels) or relative to the matched
ata, with medians (lines), interquartile ranges (whiskers) and individ-
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Chemotherapy is the main stay of treatment for rela-
tively poor prognosis breast cancers. Despite the
routine nature of this treatment, knowledge of its im-
pacts on the immune system is poor. While the focus
of breast cancer treatment rightly remains on effective
cancer cures, there is increasing recognition that
other aspects of post-treatment welfare require add-
itional attention [22, 23]. This is particularly the case
because breast cancer survival times have increased
greatly meaning that post-treatment complications
may be suffered for many years. Moreover, there is
increasing evidence that competent immune function
is involved with response to adjuvant biologic treat-
ments such as trastuzumab [24], raising the possibility
that chemotherapy-induced immune dysfunction
could render patients less responsive to modern
targeted therapies. Similarly, host immune function is
critical for a wide range of immunotherapies that are
in development [25], and careful consideration of
sequencing may be required if these are to be
combined with cytotoxic chemotherapies. Knowledge of
what impacts chemotherapy has on the immune system
may be key to using these immunotherapies effectively.
We observed that chemotherapy caused short-term
depletion of all main subtypes of circulating lymphocytes
(3-6 months), and prolonged (>9 months) depletion of B
and CD4+ T cells (Fig. 1). This is compatible with a pre-
vious smaller study showing sustained depletion of CD4
+, but not CD8+, T cells after FEC chemotherapy for
breast cancer, although unfortunately B cell were not
studied in this case [26]. We also analysed the phenotype
of the reconstituting B and T lymphocytes in detail.
Post-chemotherapy, the B cell compartment contained
an increased proportion of naïve (CD27−) cells and fewer
memory cells (CD27+), affecting both non-switched
(marginal zone) and switched (via germinal centre reac-
tions) memory B cells (Fig. 3), with an increased propor-
tion of transitional CD24hi CD38hi) B cells. CD4+ T
phenotypes showed the reverse switch, with more mem-
ory (CD45RO+) and fewer naïve cells (CD45RA+) (Fig. 4).
For CD4+ T cells, this change has been reported previ-
ously in breast cancer patients [26], although we have
expanded the observation to recent thymic emigrants,
while for B cells, this is – to our knowledge – a new ob-
servation. Relevant parallels may be drawn with lympho-
cyte repopulation following depletion by antibody or
conditioning regimens prior to hematopoietic stem cell
transplantation (HSCT). In these contexts, repopulating
B cells are also predominantly naïve with an expansion
of the transitional compartment, whilst surviving CD4+
T cells are skewed towards a memory phenotype
[27–29]. A difference, however, is that we did not see
evidence of substantially elevated (‘rebound’) numbers ofB cells during recovery, as has been reported following
HSCT [30].
Recovery post-HSCT may also inform consideration of
the longer-term immune prospects of breast cancer pa-
tients post-chemotherapy with regards to susceptibility
to infections. HSCT patients suffer lymphopenia in the
months following transplantation and are at high risk of
viral reactivations, typically earlier in recovery [31], and
are more prone to bacterial infections later, especially in
the case of delayed B cell reconstitution [32, 33]. Simi-
larly, viral reactivation is relatively common in breast
cancer patients during or shortly after chemotherapy
[34, 35], although this has not been related to depleted
lymphocyte levels. Of relevance also is that treatment
with alemtuzumab is not associated with increased sus-
ceptibility to infections and patients have normal anti-
bodies levels and vaccine responses [36, 37], although
recent reports suggest treatment-related autoimmunity,
particularly affecting thyroid and kidney [38].
We analysed antibody titres as a potential readout of
the functional impact of lymphocyte depletion and de-
termined that both anti-pneumococcal and anti-tetanus
antibody levels were significantly reduced for at least 9
months post-chemotherapy (Fig. 7), leading to an in-
creased proportion of patients clinically regarded as
lacking appropriate protection against these antigens.
Sustained repression of these antibody levels did not
correlate with low levels of any specific lymphocyte sub-
type, therefore it seems likely that reduced serum anti-
bodies related to loss of bone marrow resident plasma
cells or long-lived memory B cells. In the context of
breast cancer we believe these are novel observations,
but loss of humoral immunity to viral antigens after
chemotherapy has previously been reported in children
[39, 40]. In addition, this disconnect between B cell
numbers/phenotype and serological measures of anti-
body protective immunity is well established in the con-
text of bone marrow transplantation studies [29].
We also demonstrated for the first time that the deple-
tion extent and recovery dynamics of B and CD4+ T cells
are influenced by factors that are potentially under con-
trol of oncologists (chemotherapy regimen) or patients
(smoking) (Figs. 5 and 6). With respect to chemother-
apy, regimens of repeated anthracycline cycles were sig-
nificantly more damaging to B and CD4+ T cells than
those using anthracyclines followed by taxanes. Surpris-
ingly, while the latter combination spared B cells in the
short-term, it was associated with significantly and sub-
stantially reduced longer-term recovery. Whether these
differences relate to the cytotoxics themselves, or to the
G-CSF given with taxanes is uncertain. G-CSF is given
after every taxane cycle as a prophylactic for neutropenia
[7], but is known to mobilise hematopoietic stem cells to
the periphery [41], reportedly inhibiting B cell
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plausible that it might be a substantial influence on per-
ipheral lymphocyte levels. Smoking has previously been
associated with increased levels of both peripheral B and
CD4+ T cells [43], while we found pre-chemotherapy
levels of CD4+ T cells, but not B cells, to be significantly
higher in smokers. More interestingly, we are the first to
show smoking to be associated with reduced recovery of
B cell post-chemotherapy. This observation may relate
to reports of smoking causing impaired B cell develop-
ment in bone marrow [44] and reduced levels of periph-
eral hematopoietic stem cells [45]. The data on
chemotherapy agents and on smoking could be inter-
preted to suggest that the combination of factors that
gives the very worst recovery of B cells should poten-
tially be avoided to save-guard patients’ immune health.
Conclusion
This study has demonstrated that the adaptive immune
system is altered following chemotherapy for at least 9
months post therapy. Further investigations will be re-
quired to establish whether clinical management should
be modified to avoid the worst impacts on the immune
system, and whether revaccination against common im-
munogens should be considered in some cases.
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